Image-Guided Drug Delivery

Image-guided drug delivery refers to the combination of drug targeting and imaging. Preclinically, image-guided drug delivery can be used for several different purposes, e.g. for monitoring biodistribution, target site accumulation, off-target localization, drug release and drug efficacy. (Expert Opin Drug Deliv. 2015 Aug; 12(8): 1203)

Advances in molecular imaging modalities have accelerated the diagnosis and treatment of human diseases. However, tumors less than 1 cm in size still remain difficult to localize by conventional means because of the difficulty in specific targeting/delivery to the tumor site. Furthermore, high nonspecific uptake in the major organs and persistent background retention results in low tumor-to-background ratio. To overcome these issues, we have developed nonsticky and renal clearable theranostic nanoparticles (a.k.a. H-Dots). H-Dots not only target GIST for image-guided surgery, but also tailor the fate of anticancer drugs such as imatinib (IM) to the tumor site resulting in efficient treatment of unresectable GIST. In addition, H-Dots can monitor targetability, pharmacokinetics, and drug delivery, while also showing therapeutic efficacy in GIST-bearing xenograft mice following surgical resection. More importantly, IM loaded H-Dots exhibit lower uptake into the immune system, improved tumor selectivity, and increased tumor suppression compared to free IM, which accumulates in the spleen/liver. Precisely designed H-Dots can be used as a promising theranostic nanoplatform that can potentially reduce the side effects of conventional chemotherapies.

Iron is an essential nutrient metal, but excess iron is toxic due to increased oxidative stress caused by iron-catalyzed reactive oxygen species. Although several iron chelators are clinically used to reduce iron burden, the use of these chelators is limited due to significant adverse effects likely due to the nonspecific distribution of chelators in off-target tissues. To overcome this challenge, we developed iron chelator-coated ultrasmall nanochelators that can capture iron from plasma without distributing into non-target tissues and leave the body through urinary excretion. Our renal clearable nanochelators can decrease iron burden and reduce the risk of iron-mediated organ toxicity, with no overt chelator-related side effects.

Relevant Publications

Drug delivery system

1. Kang H, Gravier J, Bao K, Wada H, Lee JH, Baek Y, El Fakhri G, Gioux S, Rubin BP, Coll JL, Choi HS. Renal clearable organic nanocarriers for bioimaging and drug delivery, Advanced Materials. 2016;28(37):8162-8. PMID: 27414255.

2. Kang H, Stiles WR, Baek Y, Nomura S, Bao K, Hu S, Park GK, Jo MJ, I H, Coll J-L, Rubin BP, Choi HS. Renal Clearable Theranostic Nanoplatforms for Gastrointestinal Stromal Tumors, Advanced Materials. 2020;32(6):1905899. PubMed PMID: 31854033

3. Yin X, Cui Y, Kim RS, Stiles WR, Park SH, Wang H, Ma L, Chen L, Baek Y, Kashiwagi S, Bao K, Ulumben A, Fukuda T, Kang H,* Choi HS*. Image-Guided Drug Delivery of Nanotheranostics for Targeted Lung Cancer Therapy, Theranostics. 2022;12(9):4147-62. PubMed PMID: 35673583

4. Kang H, Hu S, Cho MH, Hong SH, Choi Y, Choi HS. Theranostic nanosystems for targeted cancer therapy, Nano Today. 2018; 23:59-72. PMID: 31186672.

5. Kang H, Rho S, Stiles WR, Hu S, Baek Y, Hwang DW, Kashiwagi S, Kim MS, Choi HS. Size‐Size-dependent EPR effect of polymeric nanoparticles on tumor targeting, Advanced Healthcare Materials. 2020;9(1):1901223. PubMed PMID: 31794153

6. Kang H,* Shamim M, Yin X, Adluru E, Fukuda T, Yokomizo S, Chang H, Park SH, Cui Y, Moy AJ, Kashiwagi S, Henary M,* Choi HS*. Tumor-Associated Immune-Cell-Mediated Tumor-Targeting Mechanism with NIR-II Fluorescence Imaging, Advanced Materials. 2022;34(8):2106500. PubMed PMID: 34913533

7. Yin X, Cheng Y, Feng Y, Stiles WR, Park SH, Kang H,* Choi HS*. Phototheranostics for Multifunctional Treatment of Cancer with Fluorescence Imaging. Advanced Drug Delivery Reviews. 2022;189:114483. PubMed PMID: 35944585

8. Kang H, Kang MW, Kashiwagi S, Choi HS. NIR fluorescence imaging and treatment for cancer immunotherapy. Journal for Immunotherapy of Cancer. 2022;10(7):e004936. PMCID: PMC9305898.

9. Cui Y, Park SH, Stiles WR, Yamashita A, Dihn J, Kim RS, Zhang Y, Yin X, Baek Y, Wang H, Bao K, Kang H,* Choi HS*. Renal Clearable H‐Dots Leveraging Ligand Complexation for Enhanced Active Tumor Targeting. Small Science. 2024
   
   Chelation therapy

10. Kang H, Han M, Xue J, Baek Y, Chang J, Hu S, Nam H, Jo MJ, Fakhri GE, Hutchens MP, Choi HS, Kim J. Renal clearable nanochelators for iron overload therapy, Nature Communications. 2019;10(1):5134. PMID: 31723130.

11. Park SH, Kim RS, Stiles WR, Jo MJ, Zeng L, Rho S, Baek Y, Kim J, Kim MS, Kang H,* Choi HS*. Injectable Thermosensitive Hydrogels for a Sustained Release of Iron Nanochelators, Advanced Science. 2022;9(15):e2200872. PubMed PMID: 35343104.

12. Jones G, Goswami SK, Kang H, Choi HS, Kim J. Combating iron overload: a case for deferoxamine-based nanochelators. Nanomedicine. 2020;15(13):1341–56. PubMed PMID: 32429801; PMCID: PMC7304435.

Research Team

Leader: Homan Kang, Ph.D., Assistant Professor

Members

• Min-Jun Baek, Pharm.D., Ph.D., Postdoc Research Fellow

• Won Hur, Ph.D., Postdoc Research Fellow

• Jason Dinh, B.Sc., Research Intern

• Richard Sung ki Kim, Pharm.D., Research Fellow

• Seung Hun Park, Ph.D., Instructor